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In an in vitro pharmacodynamic model, linezolid attenuated the activity of aztreonam and ceftazidime
against Escherichia coli. Conversely, synergy was detected at 24 and 48 h when daptomycin or vancomycin was
added to aztreonam and ceftazidime. We conclude that significant yet underappreciated interactions may occur
between gram-positive-spectrum and gram-negative-spectrum antibacterials.
In 2007, the U.S. Food and Drug Administration issued a
safety alert regarding the use of linezolid for presumed cath-
eter-related bloodstream infections, noting higher mortality
rates in patients treated with linezolid who were infected with
gram-negative organisms during phase 3 trials (26; K. J. Tack,
M. H. Wilcox, E. Bouza, D. H. Herr, M. M. Ijzerman, R. V.
Croos-Dabrera, and C. Knirsch, presented at the 47th Annual
Interscience Conference on Antimicrobial Agents and Chemo-
therapy [ICAAC], Chicago, IL, 2007). Linezolid demonstrates
minimal activity against gram-negative bacteria, so an expla-
nation for worse outcomes in patients receiving linezolid is not
obvious (22). However, there are cases of documented antag-
onism between beta-lactam agents and chloramphenicol, a
drug similar to linezolid, by mechanisms of action (binding to
domain V of the 50S subunit of rRNA) and resistance mech-
anisms (1, 12, 17, 19, 27, 28). Therefore, it is practical to
hypothesize that beta-lactam agents may be antagonized in the
presence of linezolid or other protein synthesis inhibitors. The
aim of this study was to evaluate the in vitro activities of
aztreonam and ceftazidime in the presence or absence of lin-
ezolid, daptomycin, and vancomycin against two Escherichia
coli strains.
(This work was presented in part at the 48th Annual
Interscience Conference on Antimicrobial Agents and Che-
motherapy [ICAAC], Washington, DC, 24 to 28 October
2008 [15].)
Escherichia coli ATCC 25922 and a clinical sputum isolate
(L1035) were tested (13). Stock solutions of linezolid (lot
no. 08E14Z99 [purchased commercially]), aztreonam (lot
no. 124K1448), ceftazidime (lot no. 117K1286), vancomycin
(lot no. 048K1457; Sigma-Aldrich, St Louis, MO), and dap-
tomycin (lot no. CDCX01; Cubist Pharmaceuticals, Inc.,
Lexington, MA) were freshly prepared and kept frozen at
20°C. All in vitro experiments were performed with cation-
adjusted Mueller-Hinton broth (Difco Laboratories, Sparks,
MD), except for daptomycin, where the calcium concentra-
tion was adjusted to 50 mg/liter. MICs were determined by
the Etest methodology and broth microdilution according to
the Clinical and Laboratory Standards Institute (6, 7).
E. coli was tested against linezolid, aztreonam, and ceftazi-
dime alone and in combination by using in vitro modeling, time
kill analyses, and two-dimensional or checkerboard screening
(mean fractional inhibitory concentration [FIC] index [FIC])
(5, 9).
Drug concentrations for time kill analyses were equal to one
(0.19 mg/ml for aztreonam and 0.19 mg/ml for ceftazidime)
and two (0.38 mg/ml for aztreonam and 0.38 mg/ml for cefta-
zidime) times the MIC of each drug. Linezolid (16 g/ml) was
used to simulate clinically achievable peak serum concentra-
tions in patients administered 600 mg every 12 h (q12h) (10).
Additionally, a previously described one-compartment in
vitro pharmacodynamic model (IVPM) provided continuous
exposure of bacteria to changing concentrations of antibi-
otics (3, 29). All model simulations were conducted over
48 h and were performed at minimum in triplicate. Calcu-
lated free-drug concentrations were simulated from the fol-
lowing total pharmacokinetic concentrations: for aztreo-
nam, 1 g q8h (half-life [t1/2], 2 h; maximum concentration of
drug in serum [Cmax], 75 g/ml; protein binding, 55%; free
maximum concentration (fCmax), 34 g/ml) (25); for ceftazi-
dime, 1 g q8h (t1/2, 2.3 h; Cmax, 60 g/ml; protein binding, 10%;
fCmax, 54 g/ml) (4); for daptomycin, 6 mg/kg of body weight
q24h (t1/2, 8 h; Cmax, 98.6 g/ml; protein binding, 92%; fCmax, 7.9
g/ml) (8); for linezolid, 600 mg q12h; (t1/2, 6 h; Cmax, 18 g/ml;
protein binding, 31%; fCmax, 12.4 g/ml) (23); and for vancomy-
cin, 1.25 g q12h (t1/2, 6 h; Cmax, 45 g/ml; minimum concentration
of drug in serum, 15 to 20 g/ml; protein binding, 55%; fCmax,
20.3 g/ml) (18). A peristaltic pump (Masterflex; Cole-Parmer
Instrument Company, Chicago, IL) was used to continually
replace antibiotic-containing medium with fresh Mueller-Hin-
ton broth supplemented with 25 g/ml calcium and 12.5 g/ml
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magnesium (at a rate to simulate the t1/2 of the respective
antibiotic). For combination regimens, the elimination rate
was set for the drug with the shortest t1/2, and the drug with the
longer t1/2 was supplemented (3). All samples were diluted
10-fold before plating in order to minimize antibiotic car-
ryover. High-performance liquid chromatography and bioas-
says were conducted as previously described (2, 14, 21).
Synergy was defined as a>2-log10 decrease in number of CFU
per milliliter between the combination and its most active con-
stituent and the point at which the number of surviving organisms
in the presence of the combination was >2 log10 CFU/ml below
the level for the starting inoculum (11). Indifference was defined
as a 1- to 2-log10-CFU/ml increase in kill in comparison to the
level for the most active single agent. Combinations that resulted
FIG. 1. In vitro activity of daptomycin alone and combined with aztreonam or ceftazidime against E. coli ATCC 25922 (a) and a clinical isolate
(b). Results show log10 numbers of CFU/ml of activity  standard deviations.
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in 2-log10-CFU bacterial growth in comparison to the level for
the most active single agent were considered antagonistic (11).
Samples taken from the model were also immediately plated
onto tryptic soy agar, and susceptibility was determined using
an Etest. In addition, a population analysis was conducted with
aztreonam and ceftazidime against E. coli (>109 CFU/ml) as
previously described (20).
Changes in number of CFU/ml at 24 and 48 h and time to
99.9% kill were compared by two-way analysis of variance with
Tukey’s post hoc test, using SPSS Statistical Software (release
14; SPSS, Inc., Chicago, IL). A P value of 0.05 was consid-
ered significant.
Both E. coli strains were susceptible to aztreonam and cefta-
zidime, with MICs of 0.25 g/ml and 0.125 g/ml, respec-
FIG. 2. In vitro activity of linezolid alone and combined with aztreonam or ceftazidime against E. coli ATCC 25922 (a) and a clinical isolate
(b).
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tively. The daptomycin, linezolid, and vancomycin MICs were
256 g/ml. Population analyses (starting inoculum, 9.98 log10
CFU/ml) demonstrated homogeneous susceptibility to aztreo-
nam and ceftazidime, with a population analysis profile MIC of
0.25 g/ml.
For combinations of linezolid plus aztreonam or ceftazi-
dime, FIC indices demonstrated indifference (FIC index  1).
Static time kill assays run at 1 and 2 the MIC with linezolid
demonstrated mean decreases of1.15 and1.42 log10 kill for
ceftazidime and aztreonam, respectively, in comparison to the
level for the most active single agent, thus demonstrating in-
difference.
In an IVPM at clinically free therapeutic concentrations,
aztreonam and ceftazidime alone and combined with dap-
tomycin (Fig. 1) or vancomycin (Fig. 2) demonstrated sig-
nificant (P  0.05) activity at 24 and 48 h. However, the
combination of linezolid with aztreonam (Table 1 and Fig.
3a) or ceftazidime (Fig. 3b) resulted in decreased activity at
24 and 48 h and represented antagonism against ATCC
25922. Indifference was noted at 24 h. Daptomycin, vanco-
mycin, and linezolid monotherapy demonstrated no signifi-
cant activity against E. coli ATCC 25922 at any time point.
However, daptomycin and vancomycin enhanced the activ-
ities of aztreonam and ceftazidime at 24 and 48 h. All
concentrations achieved within the IVPM were within 15%
of the targeted level.
In one of the eight experiments evaluating linezolid and
aztreonam in the IVPM, aztreonam-resistant subpopulations
of E. coli (MIC of 64 g/ml) were detected at 4 and 24 h. This
resistant phenotype was unstable, with three serial passages on
antibiotic-free tryptic soy agar yielding E. coli with aztreonam
MICs decreasing from 64 to 12 to 6 g/ml. Subpopulations of
E. coli with increased ceftazidime MICs were detected in one
ceftazidime in vitro model experiment at 24 and 48 h (MICs of
0.125 to 2.0 g/ml). This MIC shift was also unstable but
accounts for the larger standard deviations observed in these
experiments.
The 2007 Food and Drug Administration MedWatch alert
and a recent publication highlighted that patients with cathe-
ter-related bloodstream infection treated with linezolid had an
84-day mortality rate of 21.5% (78/363), versus the comparator
group rate of 16% (28/269) (26; K. J. Tack et al., presented at
the 47th Annual ICAAC, Chicago, IL, 2007). It was found that
baseline bacteremia caused by gram-negative organisms was a
predictor of death (K. J. Tack et al., presented at the 47th
Annual ICAAC, Chicago, IL, 2007).
TABLE 1. Activity of each antibiotic alone and combined with aztreonam or ceftazidime in an IVPM over 24 and 48 h
Antibiotic Bacterial strain
Change in no. of CFU/ml relative to 0-h levela at:
24 h 48 h
Growth control ATCC 25922 3.33  0.18 2.79  0.33
L1035 3.03  0.05 3.09  0.04
Aztreonam ATCC 25922 1.59  0.50 1.40  0.52
L1035 1.76  0.50 2.12  0.52
Ceftazidime ATCC 25922 2.83  0.29 2.70  0.24
L1035 1.35  0.31 2.07  0.30
Linezolid ATCC 25922 0.86  0.47 0.95  0.41
L1035 2.64  0.16 3.25  0.13
Daptomycin ATCC 25922 2.31  0.12 2.40  0.10
L1035 NA NA
Vancomycin ATCC 25922 2.70  0.15 3.05  0.13
L1035 NA NA
Aztreonam-linezolid ATCC 25922 0.51  0.66 (inhibited by 1.48 CFU/ml) 0.77  0.53 (inhibited by 2.56 CFU/ml; antagonism)
L1035 2.41  0.46 (inhibited by 0.80 CFU/ml) 0.63  0.45 (inhibited by 0.60 CFU/ml)
Ceftazidime-linezolid ATCC 25922 1.45  0.86 (inhibited by 1.71 CFU/ml) 0.75  0.88 (inhibited by 2.27 CFU/ml; antagonism)
L1035 1.53  0.13 (inhibited by 0.16 CFU/ml) 0.84  0.15 (inhibited by 1.25 CFU/ml)
Aztreonam-daptomycin ATCC 25922 3.75  0.03 (enhanced by 1.80 CFU/ml) 4.15  0.04 (enhanced by 2.39 CFU/ml; synergy)
Ceftazidime-daptomycin L1035 1.89  0.27 (enhanced by 0.39 CFU/ml) 2.09  0.30 (enhanced by 0.97 CFU/ml)
ATCC 25922 2.39  0.07 (inhibited by 0.30 CFU/ml) 3.94  0.08 (enhanced by 1.39 CFU/ml)
L1035 2.80  0.31 (enhanced by 2.1 CFU/ml;
synergy)
2.89  0.31 (enhanced by 1.33 CFU/ml)
Aztreonam-vancomycin ATCC 25922 3.45  0.09 (enhanced by 1.80 CFU/ml) 3.45  0.10 (enhanced by 2.0 CFU/ml; synergy)
L1035 2.89  0.25 (enhanced by 1.24 CFU/ml) 2.42  0.28 (enhanced by 1.15 CFU/ml)
Ceftazidime-vancomycin ATCC 25922 2.65  0.48 (enhanced by 0.12 CFU/ml) 3.24  0.41 (enhanced by 0.84 CFU/ml)
L1035 3.02  0.23 (enhanced by 1.92 CFU/ml) 2.60  0.22 (enhanced by 0.77 CFU/ml)
a NA, not applicable.
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Using three different methods, we examined the effects of
daptomycin, vancomycin, and linezolid on the activities of az-
treonam and ceftazidime against E. coli in vitro and found
attenuation of the activities of aztreonam and ceftazidime
against E. coli by linezolid and enhancement of aztreonam
activity against E. coli by daptomycin and vancomycin. The
reasons for these observations are not immediately clear. A
partial explanation may lie in the well-accepted notion that
bacteriostatic agents inhibit the activities of bactericidal
agents. For example, one well-known clinical study (16) dem-
onstrated that the addition of chlortetracycline attenuated the
activity of penicillin in the treatment of patients with pneumo-
FIG. 3. In vitro activity of vancomycin alone and combined with aztreonam or ceftazidime against E. coli ATCC 25922 (a) and a clinical isolate
(b).
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coccal meningitis. Patients receiving combination penicillin-
tetracycline had twofold-increased mortality compared with
patients who received the same penicillin dose as mono-
therapy.
Antagonism has been observed with antibiotics that inhibit
cell wall synthesis (e.g., beta-lactam) in combination with
agents that inhibit protein synthesis. In the case of linezolid,
the cell wall agent may be increasing the permeability of the
cell wall, allowing more linezolid to enter and accumulate
intracellularly in the E. coli, inhibiting protein synthesis appre-
ciably and consequently antagonizing the beta-lactam agent.
Previous studies demonstrate linezolid’s activity via protein
synthesis inhibition against gram-negative bacteria, including
E. coli, when there is inhibition of RND-type efflux pumps
(22).
While intriguing, the findings of this study must be inter-
preted with caution and viewed as exploratory. Other Entero-
bacteriaceae spp. and other antimicrobial classes must also be
evaluated. It is noteworthy that in the study by Wilcox et al.
(26), there was no apparent difference in microbiological out-
come between treatment arms and there were no documented
microbiological failures in either arm due to infection with
gram-negative bacteria, raising the question of whether or not
the different outcomes were related to the treatment issues
which generated the hypothesis of this study.
Nevertheless, despite these limitations, the findings of this
study have potential profound clinical implications. The use of
combination therapy in empirical regimens or those targeting
polymicrobial infections would require greater scrutiny and
point toward potential pitfalls of the “more is better” approach
that is sometimes employed clinically without supporting data.
These findings also demonstrate inconsistencies in in vitro
evaluations of the pharmacodynamic effects of antibiotic com-
binations. Finally, these data show the limitations of extrapo-
lating results obtained from traditional in vitro methods, like
checkerboards and simple time kill studies using broth, to
antimicrobial pharmacodynamics in vivo.
In summary, this study provides preliminary evidence that
antibiotics with spectra of activity limited to gram-positive bac-
teria may influence the bactericidal activities of aztreonam and
ceftazidime against E. coli. Specifically, linezolid may attenuate
the activities of cell wall agents against E. coli and may enhance
the development of resistance to these agents. Further inves-
tigation of the effect of linezolid on the activities of other
antibiotics used against other gram-negative bacteria is war-
ranted.
We thank Suzanne Woodmansee for technical assistance.
This work was unfunded. Both authors have current and previous
relationships with Pfizer, the makers of linezolid, and Cubist Pharma-
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